Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Antonio Rueda-Lara
Observed names:
A. Rueda Lara,
A. Rueda-Lara,
Antonio Rueda Lara
Institution:
Hospital Universitario Fundación Jiménez Díaz
Observed institutions:
Hospital Universitario La Paz,
Hospital Universitario Fundación Jiménez Díaz,
Centro de Investigación Biomédica en Red de Cáncer
ORCID:
0009-0003-2726-7960
Observed ORCID:
0009-0003-2726-7960
OpenAlex ID:
A5034504560
Analysis of tumor budding as a prognostic factor for recurrence in patients with stage II and III colon cancer. Experience in a tertiary hospital
2025
·
Antonio Rueda-Lara
, David Viñal
, et al.
·
The Oncologist
·
12
PDF
Prevalence and Distribution of MUTYH Pathogenic Variants, Is There a Relation with an Increased Risk of Breast Cancer?
2024
·
Jesús Peña-López
, Diego Jiménez-Bou
, et al.
·
Cancers
·
10
PDF
Clinico-Pathological Features, Outcomes and Impacts of COVID-19 Pandemic on Patients with Early-Onset Colorectal Cancer: A Single-Institution Experience
2023
·
Daniel Martinez-Perez
, David Viñal
, et al.
·
Cancers
·
10
PDF
Clinicopathological characteristics and outcomes of patients with deficient mismatch repair colorectal cancer.
2022
·
David Viñal
, Daniel Martinez-Perez
, et al.
·
Journal of Clinical Oncology
·
8
Clinical Score to Predict Recurrence in Patients with Stage II and Stage III Colon Cancer
2022
·
David Viñal
, Sergio Martinez-Recio
, et al.
·
Cancers
·
7
PDF
Novel therapies targeting delta-like ligand 3 (DLL3) in pulmonary and gastroenteropancreatic neuroendocrine carcinomas
2025
·
María Alameda-Guijarro
, Antonio Rueda-Lara
, et al.
·
Cancer Treatment Reviews
·
4
Application of GPT-4 foundation model for risk prediction and stratification in colorectal cancer.
2024
·
Antonio Rueda-Lara
, David Viñal
, et al.
·
Journal of Clinical Oncology
·
2
PDF
Prognostic value of tumor budding in patients with stage II and III colon cancer: A single-institution experience.
2023
·
David Viñal
, Antonio Rueda-Lara
, et al.
·
Journal of Clinical Oncology
·
2
2154P Total cholesterol as an independent prognostic factor in cancer patient survival: A single institution experience
2023
·
M. Alameda-Guijarro
, D. Sanchez Cabrero
, et al.
·
Annals of Oncology
·
1
PDF
P-265 Value of the Glasgow Prognostic Score (GPS) in the prognosis of hospitalised patients with gastrointestinal cancer
2023
·
J. Peña
, A. Rueda-Lara
, et al.
·
Annals of Oncology
·
1
PDF
1582P Thromboembolic disease in COVID-19 cancer patients: Impact on overall survival and prognostic factors
2021
·
A. Pertejo
, S. Martinez Recio
, et al.
·
Annals of Oncology
·
1
PDF
HLA-A*01 as a biomarker of poor outcome in patients treated with immune checkpoint inhibitors.
2026
·
Paula Villalba-Cuesta
, Tatiana Hernandez Guerrero
, et al.
·
Journal of Clinical Oncology
1798P Spread through air spaces (STAS) and its molecular landscape predict relapse after curative resection of localised lung adenocarcinoma (LUAD)
2025
·
A. Rueda Lara
, M. Alameda Guijarro
, et al.
·
Annals of Oncology
PDF
Abstract P1-12-08: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer and Use of Concomitant Proton Pump Inhibitors: Real-World Experience from a Tertiary Care Center
2025
·
Maria Alameda-Guijarro
, Jesus Peña Lopez
, et al.
·
Clinical Cancer Research
1850P Management and potential factors of immunotoxicity in patients with metastatic non-small cell lung cancer receiving first-line treatment with immune checkpoint inhibitors
2024
·
J. Peña-Lopez
, D. Jiménez Bou
, et al.
·
Annals of Oncology
P-222 Prognostic value of skeletal muscle area at diagnosis in patients with metastatic colorectal cancer: A single institution experience
2023
·
M. Rios
, D. Viñal
, et al.
·
Annals of Oncology
PDF
P-242 Characterisation of KRAS mutations in patients with metastatic colorectal cancer: A single institution experience
2023
·
M. Alameda
, A. Rueda-Lara
, et al.
·
Annals of Oncology
PDF
P-261 Oxaliplatine plus fluoropyrimidine versus fluoropyrimidine monotherapy as adjuvant treatment for stage III resected colorectal cancer (CRC) in older population, a single centre experience
2023
·
I. Ruiz-Gutierrez
, D. Jimenez-Bou
, et al.
·
Annals of Oncology
PDF
P-279 Adjuvant chemotherapy for patients with stage III colon cancer, three months vs six months. A single centre experience
2023
·
G. Martin-Montalvo
, D. Martinez Perez
, et al.
·
Annals of Oncology
PDF
Predicting recurrence in patients with stage II and III colon cancer: Validation cohort and long-term follow-up of the experimental cohort.
2023
·
David Viñal
, Daniel Martinez-Perez
, et al.
·
Journal of Clinical Oncology
PDF
Impact of COVID-19 pandemic on diagnosis, staging, and outcomes of patients with early-onset colorectal cancer.
2023
·
Daniel Martinez-Perez
, David Viñal
, et al.
·
Journal of Clinical Oncology
PDF
P-87 Clinical score to predict recurrence in patients with stage II and III colon cancer
2022
·
D. Viñal
, S. Martinez-Recio
, et al.
·
Annals of Oncology
P-41 What to expect from best supportive care as initial approach for newly-diagnosed colorectal cancer: A single institution experience
2022
·
D. Viñal
, S. Martinez-Recio
, et al.
·
Annals of Oncology
P-40 Clinico-pathological characteristics and outcomes of patients with early-onset colorectal cancer
2022
·
D. Viñal
, S. Martinez-Recio
, et al.
·
Annals of Oncology
21P COVID-19 cancer patients and thromboembolic disease: Survival analysis
2021
·
A. Pertejo-Fernandez
, S. Martínez-Recio
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
26
Citation count:
58
H-index:
5
I10-index:
3
Year
Topic
Type